{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T04:05:30Z","timestamp":1749873930684,"version":"3.41.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,13]]},"DOI":"10.7759\/cureus.85908","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T11:58:49Z","timestamp":1749815929000},"source":"Crossref","is-referenced-by-count":0,"title":["Use of Spironolactone for the Treatment of Heart Failure With Preserved Ejection Fraction: Efficacy and Clinical Implications in Light of Recent Evidence"],"prefix":"10.7759","author":[{"given":"Reeju","family":"Maharjan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damilare M","family":"Akintunde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai Jahnu Sree","family":"Reddy Narla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana C","family":"Baltodano Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai Charan","family":"Mekala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahana","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tuheen Sankar","family":"Nath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2019.09.009","article-title":"Clinical phenogroups in heart\u00a0failure with preserved ejection fraction: detailed phenotypes, prognosis, and response to\u00a0spironolactone","volume":"8","author":"Cohen JB","year":"2020","unstructured":"Cohen JB, Schrauben SJ, Zhao L, et al.. Clinical phenogroups in heart\u00a0failure with preserved ejection fraction: detailed phenotypes, prognosis, and response to\u00a0spironolactone. JACC Heart Fail. 2020, 8:172-84. 10.1016\/j.jchf.2019.09.009","journal-title":"JACC Heart Fail"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.12.057","article-title":"Spironolactone in patients with heart\u00a0failure, preserved ejection fraction, and worsening renal function","volume":"77","author":"Beldhuis IE","year":"2021","unstructured":"Beldhuis IE, Myhre PL, Bristow M, et al.. Spironolactone in patients with heart\u00a0failure, preserved ejection fraction, and worsening renal function. J Am Coll Cardiol. 2021, 77:1211-21. 10.1016\/j.jacc.2020.12.057","journal-title":"J Am Coll Cardiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2013.10.018","article-title":"Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction--results of the Aldo-DHF trial","volume":"169","author":"Edelmann F","year":"2013","unstructured":"Edelmann F, Gelbrich G, Duvinage A, et al.. Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction--results of the Aldo-DHF trial. Int J Cardiol. 2013, 169:408-17. 10.1016\/j.ijcard.2013.10.018","journal-title":"Int J Cardiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2015.07.038","article-title":"Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF)","volume":"200","author":"Capuano A","year":"2015","unstructured":"Capuano A, Scavone C, Vitale C, Sportiello L, Rossi F, Rosano GM, Coats AJ. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF). Int J Cardiol. 2015, 200:15-9. 10.1016\/j.ijcard.2015.07.038","journal-title":"Int J Cardiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.rec.2019.05.015","article-title":"Hyperkalemia in heart failure patients in Spain and its impact on guidelines and recommendations: ESC-EORP-HFA Heart Failure Long-Term Registry","volume":"73","author":"Crespo-Leiro MG","year":"2020","unstructured":"Crespo-Leiro MG, Barge-Caballero E, Segovia-Cubero J, et al.. Hyperkalemia in heart failure patients in Spain and its impact on guidelines and recommendations: ESC-EORP-HFA Heart Failure Long-Term Registry. Rev Esp Cardiol (Engl Ed). 2020, 73:313-23. 10.1016\/j.rec.2019.05.015","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2020.02.007","article-title":"Myocardial infarction in heart\u00a0failure with preserved ejection fraction: pooled analysis of 3 clinical trials","volume":"8","author":"Cunningham JW","year":"2020","unstructured":"Cunningham JW, Vaduganathan M, Claggett BL, et al.. Myocardial infarction in heart\u00a0failure with preserved ejection fraction: pooled analysis of 3 clinical trials. JACC Heart Fail. 2020, 8:618-26. 10.1016\/j.jchf.2020.02.007","journal-title":"JACC Heart Fail"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2018.03.002","article-title":"Incident hyperkalemia, hypokalemia, and clinical outcomes during spironolactone treatment of heart failure with preserved ejection fraction: analysis of the TOPCAT trial","volume":"24","author":"Desai AS","year":"2018","unstructured":"Desai AS, Liu J, Pfeffer MA, et al.. Incident hyperkalemia, hypokalemia, and clinical outcomes during spironolactone treatment of heart failure with preserved ejection fraction: analysis of the TOPCAT trial. J Card Fail. 2018, 24:313-20. 10.1016\/j.cardfail.2018.03.002","journal-title":"J Card Fail"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2011.04.007","article-title":"Results of the randomized aldosterone antagonism in heart failure with preserved ejection fraction trial (RAAM-PEF)","volume":"17","author":"Deswal A","year":"2011","unstructured":"Deswal A, Richardson P, Bozkurt B, Mann DL. Results of the randomized aldosterone antagonism in heart failure with preserved ejection fraction trial (RAAM-PEF). J Card Fail. 2011, 17:634-42. 10.1016\/j.cardfail.2011.04.007","journal-title":"J Card Fail"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher D","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009, 6:e1000097. 10.1371\/journal.pmed.1000097","journal-title":"PLoS Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.203","article-title":"Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial","volume":"17","author":"Edelmann F","year":"2015","unstructured":"Edelmann F, Holzendorf V, Wachter R, et al.. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. Eur J Heart Fail. 2015, 17:214-23. 10.1002\/ejhf.203","journal-title":"Eur J Heart Fail"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2021.01.018","article-title":"Effect of obesity on response to spironolactone in patients with heart failure with preserved ejection fraction","volume":"146","author":"Elkholey K","year":"2021","unstructured":"Elkholey K, Papadimitriou L, Butler J, Thadani U, Stavrakis S. Effect of obesity on response to spironolactone in patients with heart failure with preserved ejection fraction. Am J Cardiol. 2021, 146:36-47. 10.1016\/j.amjcard.2021.01.018","journal-title":"Am J Cardiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.12571","article-title":"Spironolactone use is associated with improved outcomes in heart failure with mid-range ejection fraction","volume":"7","author":"Enzan N","year":"2020","unstructured":"Enzan N, Matsushima S, Ide T, Kaku H, Higo T, Tsuchihashi-Makaya M, Tsutsui H. Spironolactone use is associated with improved outcomes in heart failure with mid-range ejection fraction. ESC Heart Fail. 2020, 7:339-47. 10.1002\/ehf2.12571","journal-title":"ESC Heart Fail"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-013-1512-x","article-title":"Association between spironolactone added to beta-blockers and ACE inhibition and survival in heart failure patients with reduced ejection fraction: a propensity score-matched cohort study","volume":"69","author":"Frankenstein L","year":"2013","unstructured":"Frankenstein L, Katus HA, Grundtvig M, et al.. Association between spironolactone added to beta-blockers and ACE inhibition and survival in heart failure patients with reduced ejection fraction: a propensity score-matched cohort study. Eur J Clin Pharmacol. 2013, 69:1747-55. 10.1007\/s00228-013-1512-x","journal-title":"Eur J Clin Pharmacol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1229","article-title":"Perturbations in serum chloride homeostasis in heart failure with preserved ejection fraction: insights from TOPCAT","volume":"20","author":"Grodin JL","year":"2018","unstructured":"Grodin JL, Testani JM, Pandey A, Sambandam K, Drazner MH, Fang JC, Tang WH. Perturbations in serum chloride homeostasis in heart failure with preserved ejection fraction: insights from TOPCAT. Eur J Heart Fail. 2018, 20:1436-43. 10.1002\/ejhf.1229","journal-title":"Eur J Heart Fail"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2019.09.011","article-title":"Mineralocorticoid receptor antagonists, blood pressure, and outcomes in heart\u00a0failure with reduced ejection fraction","volume":"8","author":"Serenelli M","year":"2020","unstructured":"Serenelli M, Jackson A, Dewan P, et al.. Mineralocorticoid receptor antagonists, blood pressure, and outcomes in heart\u00a0failure with reduced ejection fraction. JACC Heart Fail. 2020, 8:188-98. 10.1016\/j.jchf.2019.09.011","journal-title":"JACC Heart Fail"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01733-1","article-title":"Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis","volume":"404","author":"Jhund PS","year":"2024","unstructured":"Jhund PS, Talebi A, Henderson AD, et al.. Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis. Lancet. 2024, 404:1119-31. 10.1016\/S0140-6736(24)01733-1","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer MA","year":"2015","unstructured":"Pfeffer MA, Claggett B, Assmann SF, et al.. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015, 131:34-42. 10.1161\/CIRCULATIONAHA.114.013255","journal-title":"Circulation"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2024.05.003","article-title":"Sodium zirconium cyclosilicate in HFrEF\u00a0and hyperkalemia: REALIZE-K design and baseline characteristics","volume":"12","author":"Kosiborod MN","year":"2024","unstructured":"Kosiborod MN, Cherney D, Connelly K, et al.. Sodium zirconium cyclosilicate in HFrEF\u00a0and hyperkalemia: REALIZE-K design and baseline characteristics. JACC Heart Fail. 2024, 12:1707-16. 10.1016\/j.jchf.2024.05.003","journal-title":"JACC Heart Fail"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2024.02.021","article-title":"Previous heart failure hospitalization, spironolactone, and outcomes in heart failure with preserved ejection fraction - a secondary analysis of TOPCAT","volume":"271","author":"Szabo B","year":"2024","unstructured":"Szabo B, Benson L, Savarese G, et al.. Previous heart failure hospitalization, spironolactone, and outcomes in heart failure with preserved ejection fraction - a secondary analysis of TOPCAT. Am Heart J. 2024, 271:136-47. 10.1016\/j.ahj.2024.02.021","journal-title":"Am Heart J"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3453","article-title":"The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT-HFpEF): rationale and design","volume":"26","author":"Lund LH","year":"2024","unstructured":"Lund LH, James S, DeVore AD, et al.. The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT-HFpEF): rationale and design. Eur J Heart Fail. 2024, 26:2453-63. 10.1002\/ejhf.3453","journal-title":"Eur J Heart Fail"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.011521","article-title":"Myocardial effects of aldosterone antagonism in heart failure with preserved ejection fraction","volume":"9","author":"McDiarmid AK","year":"2020","unstructured":"McDiarmid AK, Swoboda PP, Erhayiem B, et al.. Myocardial effects of aldosterone antagonism in heart failure with preserved ejection fraction. J Am Heart Assoc. 2020, 9:e011521. 10.1161\/JAHA.118.011521","journal-title":"J Am Heart Assoc"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104795","article-title":"Treatment response to spironolactone in patients with heart failure with preserved ejection fraction: a machine learning-based analysis of two randomized controlled trials","volume":"96","author":"Kresoja KP","year":"2023","unstructured":"Kresoja KP, Unterhuber M, Wachter R, et al.. Treatment response to spironolactone in patients with heart failure with preserved ejection fraction: a machine learning-based analysis of two randomized controlled trials. EBioMedicine. 2023, 96:104795. 10.1016\/j.ebiom.2023.104795","journal-title":"EBioMedicine"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/cells10102796","article-title":"Plasma biomarker profiling in heart failure patients with preserved ejection fraction before and after spironolactone treatment: results from the Aldo-DHF trial","volume":"10","author":"Schnelle M","year":"2021","unstructured":"Schnelle M, Leha A, Eidizadeh A, et al.. Plasma biomarker profiling in heart failure patients with preserved ejection fraction before and after spironolactone treatment: results from the Aldo-DHF trial. Cells. 2021, 10:10.3390\/cells10102796","journal-title":"Cells"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.032231","article-title":"Spironolactone reduces the risk of death in veterans with heart failure with preserved ejection fraction","volume":"13","author":"Kurgansky KE","year":"2024","unstructured":"Kurgansky KE, Parker R, Djousse L, Gagnon DR, Joseph J. Spironolactone reduces the risk of death in veterans with heart failure with preserved ejection fraction. J Am Heart Assoc. 2024, 13:e032231. 10.1161\/JAHA.123.032231","journal-title":"J Am Heart Assoc"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.017683","article-title":"Longitudinal strain in heart failure with preserved ejection fraction: is there a role for prognostication?","volume":"132","author":"Mentz RJ","year":"2015","unstructured":"Mentz RJ, Khouri MG. Longitudinal strain in heart failure with preserved ejection fraction: is there a role for prognostication?. Circulation. 2015, 132:368-70. 10.1161\/CIRCULATIONAHA.115.017683","journal-title":"Circulation"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1177\/2047487317708676","article-title":"Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction","volume":"24","author":"O'Neal WT","year":"2017","unstructured":"O'Neal WT, Sandesara PB, Samman-Tahhan A, Kelli HM, Hammadah M, Soliman EZ. Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction. Eur J Prev Cardiol. 2017, 24:1212-9. 10.1177\/2047487317708676","journal-title":"Eur J Prev Cardiol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1308","article-title":"The frailty syndrome and outcomes in the TOPCAT trial","volume":"20","author":"Sanders NA","year":"2018","unstructured":"Sanders NA, Supiano MA, Lewis EF, et al.. The frailty syndrome and outcomes in the TOPCAT trial. Eur J Heart Fail. 2018, 20:1570-7. 10.1002\/ejhf.1308","journal-title":"Eur J Heart Fail"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000014967","article-title":"Efficacy and safety of spironolactone in the heart failure with mid-range ejection fraction and heart failure with preserved ejection fraction: a meta-analysis of randomized clinical trials","volume":"98","author":"Xiang Y","year":"2019","unstructured":"Xiang Y, Shi W, Li Z, et al.. Efficacy and safety of spironolactone in the heart failure with mid-range ejection fraction and heart failure with preserved ejection fraction: a meta-analysis of randomized clinical trials. Medicine (Baltimore). 2019, 98:e14967. 10.1097\/MD.0000000000014967","journal-title":"Medicine (Baltimore)"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002612","article-title":"Effectiveness and safety of aldosterone antagonist therapy use among older patients with reduced ejection fraction after acute myocardial infarction","volume":"5","author":"Wang TY","year":"2016","unstructured":"Wang TY, Vora AN, Peng SA, Fonarow GC, Das S, de Lemos JA, Peterson ED. Effectiveness and safety of aldosterone antagonist therapy use among older patients with reduced ejection fraction after acute myocardial infarction. J Am Heart Assoc. 2016, 5:10.1161\/JAHA.115.002612","journal-title":"J Am Heart Assoc"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.013637","article-title":"Regional differences in heart failure with preserved ejection fraction trials: when nephrology meets cardiology but east does not meet west","volume":"131","author":"Rossignol P","year":"2015","unstructured":"Rossignol P, Zannad F. Regional differences in heart failure with preserved ejection fraction trials: when nephrology meets cardiology but east does not meet west. Circulation. 2015, 131:7-10. 10.1161\/CIRCULATIONAHA.114.013637","journal-title":"Circulation"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.015884","article-title":"Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone","volume":"132","author":"Shah AM","year":"2015","unstructured":"Shah AM, Claggett B, Sweitzer NK, et al.. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation. 2015, 132:402-14. 10.1161\/CIRCULATIONAHA.115.015884","journal-title":"Circulation"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2014.05.010","article-title":"Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction","volume":"20","author":"Kurrelmeyer KM","year":"2014","unstructured":"Kurrelmeyer KM, Ashton Y, Xu J, Nagueh SF, Torre-Amione G, Deswal A. Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction. J Card Fail. 2014, 20:560-8. 10.1016\/j.cardfail.2014.05.010","journal-title":"J Card Fail"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.008293","article-title":"Association of hyper-polypharmacy with clinical outcomes in heart failure with preserved ejection fraction","volume":"14","author":"Minamisawa M","year":"2021","unstructured":"Minamisawa M, Claggett B, Suzuki K, et al.. Association of hyper-polypharmacy with clinical outcomes in heart failure with preserved ejection fraction. Circ Heart Fail. 2021, 14:e008293. 10.1161\/CIRCHEARTFAILURE.120.008293","journal-title":"Circ Heart Fail"},{"key":"ref34","article-title":"Spironolactone not effective in diastolic heart failure (Article in Dutch)","volume":"158","author":"Voors AA","year":"2014","unstructured":"Voors AA. Spironolactone not effective in diastolic heart failure (Article in Dutch). Ned Tijdschr Geneeskd. 2014, 158:A7805.","journal-title":"Ned Tijdschr Geneeskd"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1060","article-title":"Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial","volume":"20","author":"Selvaraj S","year":"2018","unstructured":"Selvaraj S, Claggett B, Shah SJ, et al.. Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial. Eur J Heart Fail. 2018, 20:483-90. 10.1002\/ejhf.1060","journal-title":"Eur J Heart Fail"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1177\/2047487318780035","article-title":"Efficacy of renin-angiotensin system inhibitors for patients with heart failure with preserved ejection fraction and mild to moderate chronic kidney disease","volume":"25","author":"Tsujimoto T","year":"2018","unstructured":"Tsujimoto T, Kajio H. Efficacy of renin-angiotensin system inhibitors for patients with heart failure with preserved ejection fraction and mild to moderate chronic kidney disease. Eur J Prev Cardiol. 2018, 25:1268-77. 10.1177\/2047487318780035","journal-title":"Eur J Prev Cardiol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2010.06.052","article-title":"Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure","volume":"106","author":"Vizzardi E","year":"2010","unstructured":"Vizzardi E, D'Aloia A, Giubbini R, et al.. Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure. Am J Cardiol. 2010, 106:1292-6. 10.1016\/j.amjcard.2010.06.052","journal-title":"Am J Cardiol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1194","article-title":"Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial","volume":"20","author":"Ravassa S","year":"2018","unstructured":"Ravassa S, Trippel T, Bach D, et al.. Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial. Eur J Heart Fail. 2018, 20:1290-9. 10.1002\/ejhf.1194","journal-title":"Eur J Heart Fail"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/370258-use-of-spironolactone-for-the-treatment-of-heart-failure-with-preserved-ejection-fraction-efficacy-and-clinical-implications-in-light-of-recent-evidence","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T11:58:50Z","timestamp":1749815930000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/370258-use-of-spironolactone-for-the-treatment-of-heart-failure-with-preserved-ejection-fraction-efficacy-and-clinical-implications-in-light-of-recent-evidence"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,13]]},"references-count":38,"URL":"https:\/\/doi.org\/10.7759\/cureus.85908","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,13]]}}}